# A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct04515849` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04515849](<https://clinicaltrials.gov/study/NCT04515849>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04515849

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

## Technical summary

Registry record NCT04515849. Randomized; double masking; primary purpose treatment. Start 2020-08-31 (actual); primary completion 2022-03-08 (actual). Results posted on 2025-01-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 248 participants (enrolled count; ClinicalTrials.gov record NCT04515849, source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)
- Started: 2020-08-31 (actual) (ClinicalTrials.gov record NCT04515849, source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)
- Primary completion: 2022-03-08 (actual) (ClinicalTrials.gov record NCT04515849, source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)
- Completion: 2022-03-08 (actual) (ClinicalTrials.gov record NCT04515849, source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)
- Results first posted: 2025-01-17 (ClinicalTrials.gov record NCT04515849, source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)
- Countries: Australia; Canada; Germany; Japan; New Zealand; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT04515849, source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04515849-2025-01-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Cotadutide 100 micrograms
- Intervention (Drug): Cotadutide 300 micrograms
- Intervention (Drug): Cotadutide 600 micrograms
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease (`cardio:pubmed-39218393`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9542a940dcc736b8491b14b2c9074104d018f33c7c9b6e0807e8bd5b74a56ee2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
